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To explore the expression and function of the mem-
brane-associated or type I trans glutaminase (TGasel) 
in human epidermis, we have made a new anti-
human TGase 1 antibody in goats elicited against a 
purified active recombinant protein expressed in bac-
teria. By use of Western blotting and immunopre-
cipitation methods, the antibody reacted with high 
specificity with only the TGase 1 activity of the epi-
dermis and in cultured keratinocytes. By indirect 
immunofluorescence, the antibody decorated the en-
tire epidermis, including the basal layer, with some 
potentiation of the granular layer. However, these 
staining properties are quite different from those 
of a widely used, commercially available TGasel 
monoclonal antibody (termed B.Cl), which decorates 
ne of the striking events during the process of 
terminal differentiation in stratified squamous ep-
ithelia such as the epidermis is the formation of a 
15-nm-thick layer of protein on the inner surface 
of the cell periphery, termed the cornified cell 
envelope (CE) [1-3]. The CE is now known to be assembled by the 
accumulation of several distinct proteins, including involucrin 
[4,5], cystatin A (previously known as keratolinin) [6-8], several 
small proline-rich proteins (SPRs) [7,9 -11 ], trichohyalin [12], 
loricrin [13-16], and possibly filaggrin [17,18] and keratin interme-
diate filaments [18,19].§ Although the temporal order of deposition 
and even the abundance of these structural proteins have not yet 
been established unambiguously (but see [1-3,18]), it is clear that 
they are cross-linked together by the formation of NE-(y-glutamyl) 
lysine isodipeptide bonds catalyzed by the action of at least two 
different transglutaminases (TGases) expressed in the epidermis 
[1-3,14,20]. TGase1 is membrane-associated and is expressed in 
abundance in cultured epithelial cells and in intact epider-
mis [21,22]. By use of in situ hybridization with TGase1-specific 
antisense RNA probes, TGase1 mRNA is detectable in the spinous 
Manuscript received June 28, 1994; revised August 8, 1994; accepted for 
publication September 10, 1994. 
Reprint requests to: Dr. Peter Steinert, Building 6, Room 425, NIAMS, 
NIH, Bethesda, MD 20892. 
Abbreviations: CE, cornified cell envelope; PTH, phenylthiolhydantoin; 
SPR, small proline-rich (class of proteins); TGase, transglutarninase; 
TGase1 (etc), suggested new nomenclature for transglutaminases (see [29]). 
§ Ming ME, Daryanami HA, Roberts JE, Haimowitz JE, Kvedar JC: 
Participation of mouse keratin 10 in the crosslinking of the cornified cell 
envelope ofkeratinocytes (abstr).] Invest DermatoI100:578, 1993. 
the granular layers of the epidermis. By Western 
blotting, it identifies the TGase 1 protein band only 
weakly, but recognizes strongly a group of bands of 
15-20 kDa, two of which by amino acid analysis and 
amino acid sequencing are the small proline-rich 
(SPR) 1 and SPR2 proteins, also expressed in epider-
mal and epithelial tissues. Together with a series of 
blocking experiments with TGase 1 proteins and syn-
thetic peptides, these data reveal that the major 
epitope of the B.Cl antibody most likely resides on 
the amino-terminus of these two SPR proteins rather 
than on TGase 1. Further studies will now be neces-
sary to determine the role(s) of TGasel during the 
different stages of development and differentiation in 
the epidermis. ] Invest Dermatol 104:211-217, 1995 
and granular layers of the epidermis [23,24]. However, by indirect 
immunofluorescence using a commercially available antibody 
termed B. C 1, TGase 1 protein expression appears to be confined to 
the granular layer [21,22]. Accordingly, it has been proposed that 
TGase1 mRNA is controlled post-transcriptionally in the epidermis 
[23-25]. On the other hand, TGase3 is a soluble pro-enzyme, 
requiring proteolytic activation by cleavage at a unique flexible 
hinge site about two thirds of the way along the protein [26,27]. ~ 
Although in situ hybridization experiments have not yet been 
reported, protein expression appears to occur only in the granular 
layer of intact epidermis, and it is not expressed to a significant 
extent in cultured epithelial cells [26,27].1f The precise functions or 
substrate specificities, if any, of either of these enzymes remain 
unknown. Nevertheless, based on localization of the various sub-
strates and enzymes by the use of antibodies, the notion has arisen 
that the more soluble substrates, involucrin and cystatin A, are 
deposited first and are perhaps cross-linked by TGase 1 to form a 
"scaffold" [5,18,28], to which the less soluble proteins are added 
later and perhaps cross-linked by TGase3 [1-3,18]. 
In an attempt to understand these complex processes and to test 
these hypotheses, we have begun to characterize the human 
TGase1 enzyme system [29-31]. Unfortunately, the protein is very 
unstable and is difficult to isolate or purify in quantity for direct 
biochemical experiments [22]. For this reason, we have used 
recombinant DNA and deletion cloning experiments. We have 
prepared the full-length and a series of truncated forms of TGase 1 
~ Park S-C, Kim S-Y, Kim H-C, Thacher SM, Chung S-I: Differential 
expression of transglutarninases in human foreskin and cultured keratino-
cytes (abstr).] Cell Bioi 107:139, 1988. 
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and have expressed them in bacteria [31]. In this way, we identified 
the smallest possible form of the enzyme, having the first 109 and 
last 241 amino acid residues deleted, which still retains about 50% 
of the activity of the full-length TGase 1 enzyme. We have now 
produced anew, highly specific polyclonal antibody elicited against 
this severely truncated but active form and describe its properties 
here. By indirect immunofluorescence, this new antibody indicates 
that the TGasel enzyme is expressed throughout the epidermis, 
with some potentiation in the granular layer, commensurate with 
the expression of its mRNA. This finding contrasts surprisingly 
with earlier reports with the B.el antibody. 
MATERIALS AND METHODS 
Preparation of TGases Using our full-length cDNA clone encoding 
human TGase1 (major variant) [29,30], we have prepared by polymerase 
chain reaction methods a series of 21 deletion forms, as well as the 
full-length TGase1, and subcloned them into the pET11a bacterial expres-
sion vector system (Novagen, Madison, WI) using the manufacturer's 
protocols [31]. These were expressed in the bacteria and purified to 
electrophoretic purity, and their properties and TGase activities were 
deternllned [31]. A deletion form (construct 20) having the first 109 and the 
last 241 amino acids removed was found to be the smallest form that still 
retained about 50% of the enzyme activity of the full-length (92 kDa) 
protein [30]. Guinea pig epidermal TGase3 and guinea pig liver TGase2 
were prepared exactly as described previously [26,32] . 
Preparation of TGase t Antibody The purified construct-20 recombi-
nant TGasel was used to produce a polyclonal antibody in a goat. Emulsions 
were prepared containing 0.25 rnl of the synthetic copolymer adjuvant 
(Titermax Corporation, Norcross, GA) with 0.25 rnl of protein (0.4 mg/ml 
in phosphate-buffered saline [PBS]), and 50 JLI containing 10 JLg of antigen 
was injected subdermally into the goat at 10 different sites on days 1 and 14. 
The animal was boosted at 38 d by intramuscular injection of 1 00 J.1-g at two 
sites. The highest antibody titer was attained at about 2 months, at which 
time serum was collected. The antibody was prepared by affinity purifica-
tion using the recombinant TGasel antigen conjugated to TSK matrix 
(Reacti-Gel, HW-65F, Pierce, Rockford, IL). The antibody was stored in 
0.2% bovine serum albumin solution to retain antibody activity . 
Indirect Immunofluorescence Normal adult human trunk skin was 
frozen immediately and cut into sections 6 J.1-m thick. Procedures for indirect 
immunofluorescence were followed as before [16,33,34] with our new 
TGasel antibody, the commercially available B.Cl mouse monoclonal 
antibody (used undiluted as per manufacturer's recommendation, Biomed-
ical Technologies Inc., Stoughton, MA) [21], or the loricrin carboxyl-
terminal peptide antibody SAF-I02 prepared in goats [14]. The secondary 
antibodies used were rhodamine-conjugated sheep anti-mouse IgG (Cappel 
Organon Teknika Corp., Durham, NC) or fluorescein-conjugated rabbit 
anti-goat IgG (Cappel). Sections were fixed with acetone for 10 min at 
-20°C, rinsed with PBS, and treated with 2% gelatin for 10 min. Sections 
then were incubated at 23°C with primary antibody for 30 min, rinsed, 
incubated with secondary antibody (1:300 dilution) for 30 min, rinsed, and 
mounted with 90% glycerol. Sections were observed with a BH2-RFC 
photomicroscope (Olympus) equipped with an epifluorescence illumination 
and phase-contrast device. Where necessary, double exposures with both 
antibodies were used . Antibody-blocking experiments were performed with 
either the full-length or truncated expressed forms of recombinant TGase 1. 
TGasel proteins were dissolved in PBS (200 J.1-g/ml) and mixed with 3 vol. 
of diluted TGasel or undiluted B.CI antibodies (to give a final TGasel 
concentration of 50 J.1-g/rnl). After incubation for 1 h at 23 °C, the reaction 
was centrifuged at 14,000 X g for 2 min to remove the conjugate, and the 
supernatant was used as the primary antibody. Similarly, a series of synthetic 
peptides (see below) was used to block the action of our new TGasel or 
B.Cl antibodies. A 10-mg/ml solution of peptide dissolved in PBS was 
mixed with 9 vol. of diluted TGasel or B.Cl antibody for 1 h at 23°C (to 
give a final peptide concentration of 1 mg/ml) and then centrifuged at 
14,000 X g for 2 min to remove the conjugate; the supernatant was used as 
the primary antibody. 
General Immunologic Procedures Western blots were performed 
exactly as described previously [26], using the new goat anti-human TGasel 
antibody described here at 1 :200 dilution, the previously described goat 
anti-rabbit TGase2 at a 1:100 dilution [32], and a rabbit anti-guinea pig 
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TGase3 antibody at a dilution of 1 :300. ~ Both of the latter specificall) 
cross-react with the respective human proteins. 
Immunoprecipitation reactions were performed as follows. These thre{ 
antibodies were biotinylated using standard procedures (Pierce). The thre{ 
purified TGases, either singly or in combination, were dissolved in PB~ 
solution containing the protease inhibitors leupeptin (5 J.1-g/rnl), aprotinir 
(10 J.1-g/ml), calpain inhibitor (8 JLg/ml), benzamidine (1 mM), anc 
phenylmethylsulfonyl fluoride (1 mM), and incubated with serial dilutionf 
of the biotinylated TGase antibodies for 1 h at 4°C. The immunopure 
immobilized avidin, cross-linked to 6% beaded agarose (Pierce), was then 
added to precipitate the biotinylated TGase antibodies. Mter centrifugation, 
the supernatant was assayed for TGase activity. 
Keratinocyte Protein Extracts Normal human foreskin epidermal 
keratinocytes (Clonetics, CA) were grown to confluency in KGM medium 
in 1.2 mM CaCl2 as per the manufacturer's protocol. HaCaT cells, a 
spontaneous immortalized human epidermal keratinocyte cell line [35], 
were grown to confluency in 1.8 mM CaCl2 in Dulbecco's modification of 
Eagle's medium containing 10% fetal bovine serum. In both cases, the cells 
were harvested and sonicated in 0.1 M Tris-acetate, 0.15 M NaCI, and 1 
mM ethylenediamine tetraacetic acid (EDT A) containing the cocktail of 
protease inhibitors described above. The cytosolic fraction and the mem-
brane fractions were separated by centrifugation at 10,000 X g for 30 min, 
and the latter was washed by sonication three times . 
Preparation of an Affinity Column With the B.Ct Antibody The 
IgG protein of the B.Cl antibody was purified by protein G (Pierce) column 
chromatography [36]. The eluted IgG was concentrated with YM-I0 
membranes and dialyzed against 50 mM borate buffer, pH 8.2, to remove 
primary amines such as Tris and glycine. The antibody solution was then 
mixed with immobilized protein G-agarose gel by gentle inversion for 30 
min at 23°C. After nonbound proteins were washed out with buffer, the 
complex of IgG and immobilized protein G was suspended by gentle 
inversion with dimethyl pimelimidate (6.6 mg/ml) (Pierce) for 1 h at 23 °C 
to catalyze the covalent coupling by way of the imido ester cross-linker 
between protein G and the IgG Fc region . The remaining active sites of the 
cross-linker were blocked with 0.1 M ethanolamine-HCI buffer, pH 8.2. 
Purification of the B.Ct Reacting Antigens From HaCaT Kerati-
nocytes The washed membrane fraction pellet from HaCaT keratino-
cytes was dissolved in the extraction buffer containing the nonionic 
detergent octyl-l3-glucopyranoside (1 %) to dissolve the membranes. The 
solubilized material was collected by centrifugation at 10,000 X g and then 
incubated with the immobilized B.Cl antibody overnight at 4°C. Finally, 
the bound proteins were eluted with 50 mM glycine-HCI buffer, pH 2.8, 
neutralized, and concentrated with Centricon 3 membranes (Amicon). 
Amino Acid Analysis and Sequencing The two bands I and II 
immunoprecipitated by the B.Cl antibody as described above were resolved 
on a 16% polyacrylamide gel run in tricine buffers and transferred to 
polyvinylidenedifluoride membranes . The two bands were excised, and a 
portion was hydrolyzed directly in 5.7 N HCl at 11 O°C for 22 h and then 
analyzed on a Beckman 6300 analyzer. A second portion corresponding to 
about 5 pmol of protein was hydrolyzed in 1 N HCI at 110°C for 1 h to 
remove the probable N-acetyl blocking group on the amino terminus of the 
proteins, and dried. The samples then were applied to the inert support filter 
of a Beckman LF3500 gas phase amino acid sequencer and run for 10 Edman 
degradation cycles . The phenylthiolhydantoin (PTH)-derivatized amino 
acids at each cycle were resolved and quantitated by high performance 
liquid chromatography. The PTH derivative of cysteine is unstable and 
cannot be ascertained directly, but is inferred from the appearance of 
PTH-dehydroalanine. 
Synthetic Peptides The following were synthesized, then purified by 
high performance liquid chromatography, and the compositions and con-
centrations were determined accurately by amino acid analysis [37]. The 
sequences were based on available published sequence information: 
1. Human loricrin amino-terminal [14]: SYQKKQPTPQPPVDCVK 
2. Human loricrin carboxyl-terminal [14]: VPICHQTQQKQAPTWPS 
3. SPR1 amino terminal [7,10]: NSQQQKQPCTPPPQLQQ 
4. SPR2 amino terminal [10]: SYQQQQCKQPCQPPPVC 
5. SPR3 amino terminal [10]: SSYQQKQTFTPPPQLQQ 
6. SPR2 repeat [7]: PQCPEPVKPQCPEPVKP 
7. Involucrin repeat [38,39J: LQGEQQELHKLQGEQQE 
8. Involucrin amino terminal l38]: SQQH[TLPVTLSPALSQELL] 
KTVPPPVNTHQEQ 
The 15 bracketed residues of the involucrin amino terminus were deleted to 
maximize sequence homologies with the other putative CE substrates [9]. 
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RESULTS AND DISCUSSION 
Specificity and Properties of aNew TGase 1 Antibody 
There are at least three distinct TGase activities in human epidermis 
[1-3,25]: the membrane-associated or TGase1 enzyme (approxi-
mately 92 kDa), the ubiquitous soluble or tissue TGase2 enzyme 
(approximately 80 kDa), and proenzyme TGase3 (approximately 
77 kDa). Our laboratory has undertaken a major study to under-
stand the role of each of these enzymes during terminal differenti-
ation in the epidermis. Although th~ human TGase2 and guinea pig 
TGase3 enzymes can be isolated with ease from such tissues as liver 
and skin, respectively, we have been able to produce significant 
amounts of human TGase 1 enzyme only after expression of our 
full-length cDNA clones in bacteria [31]. Polyclonal antibodies for 
TGase2 [32], TGase3,~ and a monoclonal antibody for TGase1 (B.C1 
[21]) are available. Whereas the former two are precipitating antibod-
ies, the commercially available form of the latter in our hands works 
very poorly both on Western blots and in immunoprecipitation 
reactions. Accordingly, we prepared a new polyclonal antibody in a 
goat to human TGase 1, elicited against a truncated expressed form. 
By use of an antibody-precipitation titration assay, we found that 
our new TGase1 antibody precipitated active full-length (Fig 1) or 
the various truncated TGase1 enzymes [31], so that at about a 1:300 
dilution, more than 50% of the TGase 1 activity could be precipi-
tated from solution, and virtually all activity was precipitated at a 
1:50 dilution. On the other hand, the antibody did not precipitate 
either the TGase2 or TGase3 enzyme in an identical assay, thus 
indicating a high degree of specificity (Fig 1). Conversely, the 
guinea pig TGase3 antibody precipitated only the TGase3 activity, 
and not the expressed purified TGase1 enzyme~ (data not shown). 
Under the same experimental conditions, the B.Cl antibody did 
not precipitate any of the recombinant TGase1 proteins. Further-
more, by Western blotting, the new antibody was highly specific 
for only the TGase1 protein band (Fig lb, lane 1). Similar experi-
ments have shown that this antibody cross-reacts with all of our 
expressed truncated recombinant forms ofTGase1 [31]. This means 
that its epitope(s) is located in the central core of and not the 
extreme ends of the enzyme, or on post-translational modifications 
of it. Thus, this antibody will be useful for a wide range of 
biochemical and immunologic procedures. 
Similarly, our new TGase 1 antibody recognized a band corre-
sponding to the full-length TGase 1 enzyme in the total proteins of 
cultured normal human epidermal keratinocytes (Fig 2A, lane 2) or 
of HaC aT cell line keratinocytes (Fig 2B, lane 2). In contrast, under 
these conditions, several different batches of the commercially 
available B.C1 antibody detected a band at the region of native 
enzyme only very weakly (Fig 2A,B, lanes 3). However, when we 
made a Western blot of a 4%- to 20%-gradient polyacrylamide gel 
from the same HaCaT keratinocyte extract, the B.C1 antibody 
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Figure 2. Comparison of the new TGase1 antibody and the com-
mercial B.C1 antibody by Western blotting. Cytosolic fractions (A,B) 
or total cellular extracts (G) from cultured normal human epidermal 
keratinocytes (A) or cultured HaCaT keratinocytes (B,G) were resolved on 
10% (A,B) or 4%- to 20%-gradient (G) polyacrylamide gels . Lanes 1 were 
stained with coomassie blue. La/U S 2 are Western blots using our new 
affinity-purified TGase1 antibody at 1:200 dilution. Lanes 3 are Western 
blots of the commercially available B.C1 antibody used at the manufactur-
er's specification of 1:100 dilution. Arrowhead denotes the expected size of 
the native TGase1 enzyme. Whereas the intact TGase1 enzyme was the 
major reacting species of our antibody, three bands of10-18 kDa were the 
major reactants of several lots of the B.C1 antibody. Molecular weight size 
markers are shown. 
strongly recognized a series of bands of approximately 15-20 kDa 
in size (Fig 2C, lane 3). Other investigators have not reported use 
of high-percentage polyacrylamide gels in their Western blotting 
experiments and therefore may have missed the fmding of these 
additional major precipitated protein bands. 
TGasel is Expressed Throughout Human Epidermis: Com-
parison to the B.Cl Antibody Figure 3 shows a series of 
sections of normal adult human skin examined using indirect 
immunofluorescence. Our new polyclonal TGase 1 antibody stained 
the entire epidermis (Fig 3A,D), with some potentiation in the 
granular layers . The basal layer also was stained, although at a 
reduced extent. 
In contrast, the commercially available B.C1 monoclonal anti-
body labeled only the granular layers (Fig 3B,C,E,F,H) , and in 
accordance with earlier observations [22-24], the epitope was 
2 
a 
3 1 2 
b 
3 
Figure 1. Biochemical character-
ization of a new goat anti-human 
TGase1 antibody. Left side shows 
immunoprecipitation by the new 
TGase1 antibody of only recombinant 
TGase1 protein. Right side, a, shows a 
10% sodium dodecylsulfate polyacryl-
amide gel of the purified TGase 1, 
TGase2, and TGase3 proteins (lan.es 1, 
2,3, respectively). Right side, b, shows 
a Western blot of the same gel, 
probed with the new TGase1 anti-
body. Only the TGase1 protein of 
approximately 92 kDa is recognized. 
214 KIM ET AL 1HE JOURNAL OF iNVESTIGATIVE DERMATOLOGY 
Figure 3. Comparison by Inw.rec::( Immuno8uorescence or. new TGasel antibody and eommercially av.il . ble moun monoclonal B.C! 
antibody. A.D) A 1:200 dilution "four new TGue l antibody. B,B, I-I) Undiluted eommc~ia1l y available D.CI mouse monoclonal antibody. e,F) Double 
expo,ure . C} A 1:300 dilution of SAP-t02. a goat anti-human lonerin carboxyl-terminal peptide antibody. f) Double exposur ... of B.Ct and SAF-102 
antibo<U ..... Arrows in D point to IIpparcll{ pt:npheralstaining in dtc~ .pinous layers by our new TGaKI antibody. ImageJ A-C. D-F. and G-Iare of the same 
sectionJ . tUn. SO JUII. 
localind to the cell periphef)·. COrT1!sponding to the dC!veloping 
CEo We noted during the COUtR of this srudy that the t .. ining 
pattent with the H.C! antibody w.u reminiscent ofehe localization 
of lonenn in the epidermi 113.141. By single and double immu-
nofluorescence. however. it was c1c:lr tha t although there W:IIS 
significant co-localization of tilCSC two cpitopes (Fig l G-I). mlllly 
sectiom reveal d that tbe B.Ct epilope wu expre~d sbortl) 
before loricrin (Fig 31). evertheless. these imagc1 suggest local-
ization of an antigen similar to that of the lorieno amino-terminus. 
T b e Epllope of the B .CI Antibody Ca n be Blocked by 
Synthetic P eptide. To understand why our new TGase1 anli-
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Figure 4 . Blocldng experiments with the new TGasel and the B.C. a ntibo dies. A) Our new TGasel antibody. reacted with the purified full-length 
recombinant expreued fonn of human TGasel protein. produced complete blocking. 8) D.Cl antibody, reacted with TGase l protein. produced no 
detectable blocking. TIlese results suggested to us that the epitopc of the D.Cl monoclonal antibody may in fact not reside on TGasel protein . C-J) D.C1 
antibody reacted with a series of synthetic pcptidcs (sec MntmnlJ aU/I Mt!tlIOd1) , including amino-tenninal peptide for SPRI (G). SPR2 (D) , and SPRJ (E); 
repeating peptide of SPR2 (H); loricrin amino-tenninal (f) or carboxyl-terminal (G) peptide); involucrin repeating peptide containing cross-linking 
glutamine residue (I): or modified amino-tenninal peptide (f) . Note that [he SPR2 amino-terminal peptide results in complete blocking. TIle other synthetic 
pcptides resulted in only panial blocking o r nOlle at all. 
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Figure 5. C h arac t erizatio n of the maj o r a n t ige.n recogni.xed by th e 
D.C I antibody of H aC aT keratinocytes. A) Coont3uic-5tained 40/ .... [0 
200/_gradienr polyacrylamide gels of the following: IlItI ~ I. total cytosolic 
fraction from l-IaCaT ceLIs: la,. t" 2. l1ouionic det~gelll-soluble component of 
tllC membrane fraction: and 'a,,~ J . no njonic detergent-insoluble component 
of the membrane fraction. 8) W cstern blot of A . q CoomaSS1L--uained 16% gc.l 
of the affinity-purifiL-d antigens of the inllnobiliZL-d protein G-ab>WOSC B.e l 
antibody. The two bands I and 1/ corresponding to the middle and lower bands 
of A. I.",~ 2. and B. la,,~ j were excised for amino acid analysis and .sequencing. 
A"vwlltad denotes intaCt TGasel enzyme. Asurisk in C dcnoc:cs IgG heavy 
chain protein. Molecular weight size markel'S are shown. 
body and dle B.C I antibody give different scauung partems. we 
performed a series of control experimencs. First, it seemed possible 
that the epitopes of our TGase l antibody and thar ofB.Cl might be 
different because of the truncated size of the immunogen used {O 
prcpare our antibody. Blocking experimencs with cither the ex-
presscd uuncaccd immunogen (not sbown) or the expressed full-
length TGase I protein completely eradicated staining witb our 
antibody (Fig 4A). Howcvcr. neither of these recombinant TGasel 
proreins significantly interfered with staining by the B.C ! antibody 
(Fig 4B). Second, from the results of Fig 38 .B.H . synthetic 
pep tides were prepared from the known sequences of scvcrallikely 
CE TGase substrate proteins. including loricrio tenninal peptide 
sequences. a repeating sequence of involucrin. corresponding to 
known cross-linking peptide sequence sitcs [14.391. as well as 
membe rs of tbe SPR class of proteins. It is interesting that each of 
these possess remarkably conse rved sequences [9J. Although DO 
direct biochcmical proof exists yer, this sequence homology implies 
thai' these Iysille- and glutam ine-rich sequences may all be involved 
in cross- linking I"eactions [91 , because the similar sequences on the 
loricrin carbox y-temlinus contain known cross- linking sites [14]. 
We found that the SPIU ammo-tenninal peptide completely 
abolished sraining of the H.C I antibody (Fig 4D). whereas rhe 
amino-renninal SPR 1 (Fig 4C). SPR3 (Fig 4E). and SPlU repeat-
ing peptides (Fig 4H) produccd only slight reductions in staining. 
likewise. the loricrin amino- and carboxyl-terminal peptides (Fig 
4FJ G, respectivel y) and the two involucrin peptides (Fig 41J) 
resulted in reduction of staining. Several contro l peptides of 
unrelated sequences and of equivalent siz.e. including the carbox-yl-
lcmlini of human keratil1$ I and lO [33] and several portions of 
human and mouse filaggrin [40) . did not interfere with staining by 
the 8.C! antibody (data not shown). T he larccr comrols were 
chosen because these proteins may also be potential substrates for 
epidemlal TGases [17-19).§ Furthemlore, none of these peptidcs 
blocked the action of our new TGasel antibody (data no t shown) . 
These blocking experimenrs suggest that the major cpitope of the 
H.C ! antibody does not reside on the TGase I protein backbone or 
on a post-translational adduct of it [4! .42), as neither the synthe ti c 
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peptides nor the bacterially cxpl"cssed proteins [43J we re 1l10dHied 
after synthesis . 
T h e Major Epitope of the B. C1 Antibody Resides o n the 
SPRl Prote in To confi rm that the major epitope of the H.C! 
antibody in fact resides on the SPit proteins. we chamcterized 
further lhe nature of the pl"oteins seen in F ig 2e. la"e 3 thar were 
in11l1unoprecipitated by dle B.C I an tibody. The cycosolic and 
membrane fractions of HaCaT keratinocytes were prepared essen-
tially as described previously [211 for squamous cell carcinoma cells 
to generacc the antigen used in the manufactul"e of the B.C 1 
antibody. However, we next solubilized m,e membrane fraction 
with a non-ionic detergent (octyl-IJ-glucopyranoside). and the 
rcsulting soluble and insoluble components (Fig SA. lanes 2 alld 3. 
respectively) were rhen immunoprecipitated with the B.C I anti-
body (Fig 58 . lalles 5 mId 6). Two prominent bands of about 18 and 
10 kOa were idencified (Fig SC). These are the same as the middle 
and lowe r bands seen in Fig 2C. lalle 3 and F ig SA. I(lII t 2. By 
amino acid analysis (Table I). these two bands are chemically very 
similar to the SPR proteins I and 2. respectively. which arc also 
exp ressed abundantly in the epidemlis and in cultured kerarinocytcs 
[7.10. 11 1. This was cxplored fu rther by d irect amino acid scquenc-
ing for 10 cycles. These bands displayed 90% and t 00% of sequence 
identity to dle amino temlini of tile human SI'R 1 and SPR2 
protcins. respectively (Table 0). 
[n combination , these data therefore suggcSt that the major 
cpitope of the B.C t antibody resides on me SPR2 protein expresscd 
in the epidennis and in othe.r strdcificd squanlous epithelia . 
C oncluding R emarks The S .C I monoclonal antibody was 
elicited against an insoluble membrane fraction obtained from 
squamous cell ca rcinoma- 13 cell s grown in culwl"c that had been 
treated with 12-0-tetradec:moyl-phorbol- 13-acetare r21] . T his 
fraction retained TGase activity [2 11. but the exact enzyme present 
was no t con finned. Moreover. it coutained other prou:in SpCciCli 
that, wc show here, included members of the SPR class o f protcins. 
It is interesting that several studies have shown elevated expres-
sion of both the IllRNA and levels of the SI'RI. -2. and -3 proteins 
after 12-0-tetradecalloyl-phorbol-13-acetate ueatlllent of nonnal 
or transfomlcd keratinocytes [7.11.44.45]." AldlOUgh dle original 
stock of B.Cl monoclonal antibody contained a significant titer 
•• Vaar M. Eller MS. Afridi N. Harkness DD. Gilchrest SA: SPit! ge.ne 
expreuiol1 in skin: a novel marker for kerarinocyte differentiation and 
growth ces~ation (abstr).} ,,,"at Drnttalol 100:584. 1993. 
Table I. Amino A cid C ompositions (rcs/ l00 res) o f T w o 
Proteins lmmunoprecipita ted by the B .Cl Ant ibody: 
SimiJa rity to SPR Prote ins" 
Human Human Human 
Amino Acid .nand I Band II SPRI SPR.2 SPit:) 
Asp/Asn Trace 2.6 1.12 0 1.20 
n" 6.2 2.8 5.62 2.78 10.18 
5<, 3.' 5.2 2.25 4.17 3.5' 
GIn/ Gin 27.1 13.2 26.94 19.45 17.96 
Pro 25.4 36.3 30.34 38.89 22. 16 
Gly Trace Trace 0 0 8.38 
AI, 5.8 1.1 2.25 0 1.20 
V,) Tl"ace 2. 1 5.62 2.78 8.98 
Cy' 13.5 13.8 8.99 15.28 4.7' 
Mcc Trace 0.9 1.1 2 1.39 0 
lie 1.9 Trace. 2.25 0 2.99 
Leu Trace Trace 0 0 1.20 
Phe Trace Trace 0 0 2.4 
T)" Trace 4.1 (I 4.17 2.40 
Hi> 2.5 1.4 1.12 0 0.6 
Ly' 8.8 12.1 12.36 11.11 11 .98 
A,S 2.R Trnce 0 0 0 
• COIl1posiriQlI1 ofhunlan SIll\. proudll) are from (1 01. Trace is leu lh3.11 0.5%. 
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Table D. &nino Acid Sequcnces of Two Protcins lnununoprccipitated by thc B.Ct Antibody Corrcspond to SPR Proteins" 
B:md I: S S Q Q Q K Q p Ie) T 
Band II; S y Q Q Q Q Ie) K Q p 
Human 
SPRI N S Q Q Q K Q I' C T I' P P Q 
Human 
SPIU S Y Q Q Q Q c K Q I' C P P P 
Hwnan 
SPIU S S y Q Q K Q T F T P I' Q L 
• NOII$ Single_leIIL'1'" rode for amino acids is used. Sequenc'"-S of bum an SI"" pnxdns arC': from 1101. PTH-C cannot Ix delcmlined directly b)' the tequcncing ~)'jle':1Il uJed becaUJI: 
it b degndcd; iu prelel1Ce i5 inferred from the appearanct: of P11i-deh)'dr(t;(lanine. a bre~kdown produci of I'TH-C. 
of :uui-TGase 1 activity as evidenced by Westero blotting experimenrs 
12IJ, our inununologic and protein chemistty dara describt..-d here 
establish that the major epitopc of several batches of the conunc.rcially 
available fonn oC the antibody resides on the SPR proteins. 
Our new data establish that TGase I is expressed throughout 
normal human cpidennis (Fig 2) . Thus. our data show that TGasel 
prOl'cin appears coincident with its mRNA [23.24], and indicate 
thar 3 proposcd complex mechanism of rcgulation of TGase 1 
expression by thc prccranslational control of its mRNA 123-25} is 
no longer necessary. Funher studics will now be necessary to 
determine t.he function and substrate specificity of the TGasel 
enzyme during tcmlinal diEcrcnoation in the epidermis and in other 
nnltified squamous epithelia . 
Wt .:I" i"ddllN III DrY. U1rik~ Utlui and Stuan YUJPQ for Ihrir (hallmtillg and 
Ittlpfill diMuuioll$ Jljri",~ tilt COUf'1t Df litiS u~rk, 
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